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Abstract
B-cells can contribute to the pathogenesis of autoimmune diseases not only through auto-antibody secretion but also via
cytokine production. Therapeutic depletion of B-cells influences the functions and maintenance of various T-cell subsets.
The mechanisms governing the functional heterogeneity of B-cell subsets as cytokine-producing cells are poorly
understood. B-cells can differentiate into two functionally polarized effectors, one (B-effector-1-cells) producing a Th-1-like
cytokine pattern and the other (Be2) producing a Th-2-like pattern. IL-12 and IFN-c play a key role in Be1 polarization, but
the initial trigger of Be1 commitment is unclear. Type-I-interferons are produced early in the immune response and prime
several processes involved in innate and adaptive responses. Here, we report that IFN-a triggers a signaling cascade in
resting human naive B-cells, involving STAT4 and T-bet, two key IFN-c gene imprinting factors. IFN-a primed naive B-cells for
IFN-c production and increased IFN-c gene responsiveness to IL-12. IFN-c continues this polarization by re-inducing T-bet
and up-regulating IL-12Rb2 expression. IFN-a and IFN-c therefore pave the way for the action of IL-12. These results point to
a coordinated action of IFN-a, IFN-c and IL-12 in Be1 polarization of naive B-cells, and may provide new insights into the
mechanisms by which type-I-interferons favor autoimmunity.
Citation: de Goe ¨r de Herve M-G, Durali D, Dembele B, Giuliani M, Tran T-A, et al. (2011) Interferon-Alpha Triggers B Cell Effector 1 (Be1) Commitment. PLoS
ONE 6(4): e19366. doi:10.1371/journal.pone.0019366
Editor: Derya Unutmaz, New York University, United States of America
Received December 6, 2010; Accepted April 2, 2011; Published April 29, 2011
Copyright:  2011 de Goe ¨r de Herve et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yassine.taoufik@bct.aphp.fr
Introduction
B cells produce cytokines in response to a broad array of stimuli,
including microbial products, antigens, and T cells [1,2].
Cytokine-producing B cells have been identified in blood and
lymphoid tissues of mice and humans with autoimmune disorders
and infections [1,3,4]. Cytokines secreted by B cells can modulate
the differentiation and functions of several key immune effectors,
such as CD4 and CD8 T cells, NK cells and dendritic cells [5].
This could explain the antibody-independent immunoregulatory
functions of B cells observed in several experimental models of
infection and autoimmunity [1,3,4]. B cell depletion by rituximab,
a mouse-human chimeric antibody specific for CD20, has been
tested in various hematological and non-hematological autoim-
mune diseases [5,6]. Interestly, rituximab can induce extended
periods of clinical remission from autoimmune disorders without
significantly reducing serum autoantibody titers [7]. In parallel to
this clinical benefit, rituximab has been reported to modulate the
numbers and functions of regulatory T cells and T cell effectors in
several autoimmune diseases [5,6]. This supports the emerging
concept that B cells may have a pathogenic action which is
independent of their antibody production [1]. The mechanisms
that control cytokine production by B cells are therefore drawing
increasing attention. B cells can differentiate into two distinct Th-
1-like and Th-2-like effector subsets that produce distinct
polarizing cytokines such as interferon (IFN)-c and interleukin
(IL)-4, respectively [5,8,9,10,11]. IFN-c is a key immunoregulatory
cytokine and a hallmark of Th-1 responses. We have previously
shown the key role of IL-12 and IFN-c in the generation of IFN-c-
producing B cells [8]. IL-12 triggers STAT4 activation and IFN-c
production by B cells independently of T-bet, which is not directly
induced by IL-12. IFN-c in turn triggers STAT1 activation, T-bet
expression, and also its own expression through an autocrine loop
[8]. In this IFN-c double-wave model, IFN-c acts downstream
of IL-12. However, IFN-c is a major inducer of IL-12Rb2
expression, a key component in IL-12 signaling [8], raising the
possibility that IFN-c or another, unidentified IL-12Rb2-inducing
factor may also act upstream of IL-12. The initial source of IFN-c
could be innate immune cells such as NK cells or cd T cells, or B
cells themselves, via a third player released early in the immune
response. Type I interferons (IFN-a/b) are induced early in the
immune response and provide a priming mechanism that
orchestrates several subsequent processes involved in innate and
adaptive immune responses [12]. They are also involved in the
pathogenesis of several systemic and organ-specific autoimmune
diseases [12]. Like IL-12, type I IFNs signal through STAT4 and
promote IFN-c secretion by human T cells and mouse T and NK
cells [13,14,15,16,17,18]. STAT4 activation by type I interferons
is critical for the IFN-c response to viral infections in mice [16].
Here we examined the effects of IFN-a on Be1 polarization.
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IFN-a induces STAT4 activation and T-bet expression in
human B cells
IFN-a induces STAT4 activation and T-bet expression in
human B cells. Type I IFNs share a heterodimeric receptor
composed of IFNAR1 and IFNAR2 subunits [12]. IFNAR2
appears to serve as the ligand binding chain, but both chains are
required for signal transduction [12]. IFNAR1 and IFNAR2 were
both expressed at the surface of human resting B cells, with no
significant difference in the levels of expression between CD27
2
naive and CD27
+ memory B cells (Fig. 1A). We used highly
purified human B cells to examine IFN-a signalling (Fig. 1B).
Western blot analysis showed that IFN-a phosphorylates STAT2
in human B cells (Fig. 1C) This was consistent with what was
observed in T and NK cells [14,19,20]. In those cells, it has been
shown that PSTAT2 may serve as an adaptor for the recruitment
and phosphorylation of STAT1 and, possibly, STAT4 [14,19,20],
although STAT4 phosphorylation has been observed in response
to type I IFN in STAT2-deficient NK cells [15]. B cells
constitutively expressed STAT1 and STAT4, while no pSTAT1
or pSTAT4 was detected in untreated cells (Fig. 1D). Cell
treatment with IFN-a led to tyrosine phosphorylation of STAT1
and STAT4 (Fig. 1D). No significant nuclear localization of
STAT1 and STAT4 was observed in untreated cells, while IFN-a
treatment induced nuclear translocation of both factors (Fig. 1D).
We used flow cytometry to follow the activation kinetics of STAT1
and STAT4 upon IFN-a exposure. We found sequential kinetic
patterns (Fig. 1E): STAT1 activation peaked at 1 hour and had
returned to baseline by the time STAT4 activation peaked, after
approximately 12 hours (Fig. 1E). No significant difference was
found between CD27
2 naive and CD27
+ memory B cells in terms
of STAT1 and STAT4 phosphorylation levels or kinetics (not
shown). This pattern of sequential activation might be related to
the relative abundance of STAT1 and STAT4 or to the
involvement of suppressor of cytokine signaling (SOCS) proteins
such as SOCS1, which inhibits STAT1 activation [21].
T-bet is a key transcription factor for both Th-1 and Be1
differentiation [8,9], and its expression is under the control of
STAT1 [22]. Both naive and memory B cells constitutively
expressed T-bet (Fig. 2A, 2B). As IFN-a activated STAT1 in B
cells, we examined the effect of IFN-a on T-bet expression. We
found that IFN-a induced a rapid increase in T-bet expression,
with a maximum 1 h after activation and a subsequent rapid fall
(Fig. 2A). The kinetics of T-bet expression by B cells on IFN-a
exposure matched the kinetics of STAT1 activation (Fig. 1E, 2A).
By contrast to STAT1 and STAT4, the T-bet-inducing effect of
IFN-a mainly concerned the naive subset (Fig. 2B).
IFN-a may pave the way for Th-1-like B cell differentiation
STAT4 and T-bet are two IFN-c gene imprinting factors
crucial for Th-1-type differentiation [23,24,25]. As shown in
Fig. 2C and 2D, treatment of human resting B cells with IFN-a led
to detectable IFN-c mRNA expression. By contrast, IFN-a had no
effect on the mRNA expression of IL-12 p40 or of Th-2-type
cytokines (Fig. 2C). This was consistent with the lack of effect of
IFN-a on the activation of STAT6 (not shown), a key regulator of
IL-4 and IL-13 gene expression. IFN-a induced barely detectable
IFN-c secretion by resting B cells (Fig. 2E). The mitogenic and
polyclonal B cell activator Staphylococcus aureus Cowan strain (SAC)
induces B cell activation via BCR and Toll-like-receptor 2
stimulation [26]. B cell treatment with IFN-a prior to activation
with SAC triggered higher mRNA expression and IFN-c
production (Fig. 2D, 2E). Flow cytometry showed that the naive
CD27
2 B cell subset was mainly responsible for this IFN-c
expression (Fig. 2F). These results suggested that IFN-a may prime
naive B cells to produce IFN-c. Activation of B cells with IFN-a
and anti-CD40, anti-IgG, or with a combination of anti-Ig and
anti-CD40 did not lead to significant IFN-c production (not
shown), suggesting that the IFN-c-inducing effect of IFN-a
requires additional signals such as TLR signaling, in keeping with
previous observations suggesting that TLR signaling is required for
optimal naive B cell activation [27,28]. However isolated TLR2
activation had no effect on IFN-c expression [29].
We have previously reported that IFN-c induces T-bet
expression in B cells [8]. Interestingly, the T-bet-inducing effect
of IFN-c observed here appeared to last longer than that of IFN-a
(Fig. 3A) and affected naive and memory subsets to similar extents
(Fig. 3B). Another cytokine critical for Be1 and Th-1 commitment
is IL-12, and a key step in Th-1 differentiation is the induction of
IL-12Rb2, which is required for effective IL-12 signaling. IFN-c
increased IL-12Rb2 expression in both naive and memory B cells
(Fig. 3C), while IFN-a had no clear effect on IL-12Rb2 expression,
(Fig. 3C). This suggests that IL-12 may mainly act downstream of
IFN-a-induced IFN-c in B cells. This is also in line with the
observations that IFN-c may prime IL-12 production by
phagocytic cells [30,31,32]. Next, we pre-treated resting B cells
with IFN-a, this induced STAT4 activation and T-bet expression
as shown above but led only to barely detectable IFN-c secretion,
in the absence of BCR and Toll-like-receptor 2 stimulation
(Fig.2E). Despite the lack of significant IFN-c secretion and IL-
12Rb2 upregulation, IFN-a enhanced IFN-c expression in
response to IL-12 (Fig. 3D). This suggested that the effects of
IFN-a on IFN-c gene synergize with those of a subsequent IL-12
signaling. Therefore, in addition to allow an initial burst of IFN-c
following appropriate B cell antigenic activation, IFN-a may
possibly induce epigenetic modifications in the IFN-c gene that
increase responsiveness to IL-12 (Fig. 3D).
Concluding Remarks
Together, our results identify IFN-a as an initial trigger of Be1
commitment and point to sequential Be1 phenotype imprinting of
naive cells by IFN-a, IFN-c and IL-12, via the action of STAT4
and T-bet. IFN-a triggers IFN-c production, which in turn
promotes IL-12 production by surrounding dendritic cells. IFN-a
and IFN-c enhance B cell responsiveness to IL-12, by increasing
IFN-c gene responsiveness to IL-12 signaling and inducing the b2
component of IL-12R, respectively. The cascade of events
triggered by the initial IFN-a signal may therefore prepare the
ground for the action of IL-12, which, through sustained effects on
STAT4 activation, IFN-c and T-bet expression may imprint a Th-
1-like phenotype on B cells. IL-12 also increases IL-12Rb2
expression [8,33].
IFN-a is widely used in the treatment of viral hepatitis, owing to
its role in antiviral defenses. However, accumulating evidence also
points to a role of IFN-a in the pathogenesis of various
hematological, solid organ and systemic autoimmune diseases
[12]. The Be1-promoting effect of IFN-a along with the resulting
regulation of T cell responses through cross-regulation of Be1/Be2
and Th-1/Th-2 subsets, could be a key factor in the beneficial and
deleterious effects of IFN-a.
Materials and Methods
Ethics Statement
Human lymphocytes were isolated from anonymous buffy coats
obtained from healthy blood donors and provided by the
Etablissement Franc ¸ais du Sang (EFS), Hopital S
t Louis, Paris,
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Hopital S
t Louis and INSERM. Informed consents were obtained
from the donors by the EFS, Hopital S
t Louis. The Bice ˆtre hospital
local ethics committee waived the need for study approval.
Cells
Highly purified B and T cells were obtained from peripheral
blood mononuclear cells (PBMC) following CD19 and CD4
selection in a magnetic separation system, as recommended by the
Figure 2. IFN-a induces T-bet expression in B cells and primes B cells for IFN-c production. In 2A, T-bet mRNA expression at rest, assessed
by RT-PCR, in untreated sorted naive and memory B cell subsets is shown. T-Bet expression was also quantitatively analyzed quantitative RT-PCR in
total B cells after IFN-a treatment. Results are expressed as fold increases versus untreated total B cells. In 2B, T-bet mRNA expression was analyzed in
sorted naive and memory B cell subsets after IFN-a treatment for 6 hours. 2C, B cells were treated for 24 h with IFN-a, and cDNAs were amplified with
primers for IFN-c, IL-12 p40, IL-12 p35, IL-4, IL-5, IL-13 and GAPDH. Positive controls consisted of the EBV-transformed B cell line RPMI-8866 (which
constitutively expresses IL-12p35 and IL-12p40) and anti-CD3-activated T cells. 2D, 2E: B cells pretreated with IFN-a for 18 hours were treated with
SAC for 24 hours (for mRNA quantification, 2D) or 48 hours (for ELISA, 2E). The corresponding cDNA and supernatants were assayed for IFN-c
expression by quantitative PCR and ELISA, respectively. Fig. 2F shows IFN-c expression in naive and memory B cell subsets after IFN-a pretreatment
and SAC activation for 12 hours, as determined with flow cytometry. Dashed lines correspond to isotype control. Data are representative of 4
different donors (2C, 2F) or are mean6 SEM of 6 to 7 different donors (2A, 2B, 2D, 2E). Statistically significant differences are indicated by an
asterisk.
doi:10.1371/journal.pone.0019366.g002
Figure 1. IFN-a induces STAT4 activation in human B cells. In 1A, IFNAR1 and IFNAR2 expression was analyzed in the CD3
2CD19
+CD27
+ and
CD3
2CD19
+CD27
2 lymphocyte gates. A representative staining profile is shown in the left-hand graph. The right-hand graph represents corrected
mean fluorescence intensities (MFI) of IFNAR1 and IFNAR2 after substraction of MFI values obtained in isotype control in naive (CD27
2) and memory
(CD27
+) B cell subsets. The results correspond to the mean 6 SEM of the values obtained with cells from 6 healthy donors. 1B shows the purity of B
cell preparations (see methods). In 1C, purified B cells were activated with IFN-a for 1 h then lysed. Western blotting was performed on whole-cell
lysates by using anti-phospho-STAT2, and the membranes were reprobed with anti-STAT2. The data shown in 1C are representative of 2 independent
experiments. 1D, left panel: B cells were activated for 1 hour with IFN-a. Western blotting was performed on whole-cell lysates by using anti-
phospho-STAT1 or anti-phospho-STAT4. The membranes were then reprobed with anti-STAT1 or anti-STAT4. The data shown in 1D, left panel are
representative of 2 independent experiments. 1D, right panel: B cells were activated with IFN-a for 1 hour or left untreated. They were then fixed,
permeabilized, and stained with anti-STAT4 or anti-STAT1 (green) plus propidium iodide (nuclear staining, red). Nuclear translocation was examined
by confocal microscopy. Yellow spots indicate nuclear STAT. Similar results were obtained in three other experiments. In 1E, the kinetics of STAT1 and
STAT4 phosphorylation was analyzed in B cells by flow cytometry with phospho-STAT-specific antibodies. A representative staining profile is shown
in the left-hand graph. The right-hand graph represents corrected mean fluorescence intensities (MFI), after subtraction of MFI values obtained in
isotype controls, of phospho-STAT1 and phospho-STAT4 in B cells. The data shown in 1E are the mean 6 SEM for cells from 4 healthy donors.
doi:10.1371/journal.pone.0019366.g001
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flow cytometry with CD3, CD14, CD16, and CD22 staining
(Becton Dickinson). The Epstein-Barr virus-positive (EBV
+) B-cell
line RPMI-8866 was obtained from the European Cell Culture
Collection (ECACC). B cell purity was assessed by flow cytometry
after CD3, CD14, CD16 and CD22 staining (Becton Dickinson)
and always exceeded 98%.
Flow cytometry
For pSTAT4 and pSTAT1 staining, purified B cells were fixed
and permeabilized in cold methanol, then washed and stained for
intracellular pSTAT1 or pSTAT4 (BD Biosciences). IFNAR1 and
2 surface expression was examined by using PE-labeled anti-
IFNAR2 and FITC-labeled anti-IFNAR1 (R&D systems).
RT-PCR and quantitative RT-PCR
Purified B cells (2610
5/0.2 ml/well) were cultured in 96-well
plates in RPMI 1640 medium (Gibco) supplemented with 10%
FCS (Biochrom). B cells were activated for up to 72 h with
recombinant human IFN-a2b (2000 U/ml) (Schering-Plough
S.A.), Staphylococcus aureus Cowan I (SAC, 1:10 000 v/v) (Pansorbin,
Calbiochem) or a combination of IFN-a2b and SAC. RNA
Figure 3. IFN-a increased IFN-c gene responsiveness to IL-12. 3A, B cells were treated for various times with IFN-c, and T-bet mRNA
was quantified by RT-PCR. The results are expressed as -fold increases versus untreated cells. 3B: T-bet mRNA -fold increases are shown for the
naive and memory subsets at the 6-hour time point. 3C: Purified naive and memory B cells were activated for 6 hours with IFN-a or IFN-c. IL-12Rb2
mRNA expression was analyzed by quantitative PCR. 3D: B cells were pretreated with IFN-a for 18 h and treated with IL-12 for 24 h, then IFN-c and
GAPDH cDNAs were quantified by PCR. The results are mean 6 SEM of values obtained with cells from 4 (3B, 3C)o r6( 3A, 3D) donors. Statistically
significant differences are indicated by asterisks.
doi:10.1371/journal.pone.0019366.g003
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performed as previously described [8]. The IFN-c, IL-12p40, IL-
12p35, IL-4, IL-5, IL-13 and GAPDH primers and the T-bet
primers and probes used here are described elsewhere [8].
T-bet, IFN-c, IL-12Rb2, and GAPDH cDNA levels were
determined by using Light Cycler-based kinetic quantitative PCR
(Roche Diagnostics), as previously reported [8]. To correct for
variations in RNA recovery and in the reverse transcription yield,
the amounts of T-bet and IFN-c cDNA were divided by the
amount of GAPDH cDNA [8]. T-bet results were expressed as -
fold differences in normalized values relative to untreated control
cells [8].
Measurement of STATs
96-well plates were coated for 1 hour at 37uC with poly-L-
ornithine and washed 3 times. Thirty thousand purified B cells per
well were cultured overnight, then activated with IFN-a2b
(2000 U/ml) for various times. The cells were fixed and total
STAT4 and total STAT1 were quantified with Elisa methods, as
recommended by the manufacturers (STAT4 ELISA, R&D
Systems; STAT1 ELISA, Ray-Biotech).
Confocal microscopy
For confocal microscopic analysis of STAT4 and STAT1
expression, cells were treated with IFN-a2b (2000 U/ml) for
1 hour at 37uC, washed, fixed and permeabilized, then incubated
with 10 mg/ml rabbit polyclonal IgG against human STAT4 or
STAT1 (Santa Cruz). Indirect immunofluorescence analysis was
performed by incubating cells with an Alexa Fluor 488-labeled
goat anti-rabbit IgG antibody (10 mg/ml, Molecular Probes). In
control experiments the specific antibodies were replaced by a
rabbit IgG isotype control (Santa Cruz). Nuclear staining was
performed with propidium iodide (250 ng/ml, Sigma Aldrich).
After staining, the cells were washed with PBS, centrifuged in a
Cytospin 3 (Shandon) and analyzed by laser scanning confocal
microscopy with the Leica TCS Confocal System.
Western blot
Purified B cells were incubated in RPMI 1640 medium
containing 10% FCS and treated with IFN-a2b (2000 U/ml) for
1 h at 37uC. They were then washed with PBS containing 50 mM
sodium orthovanadate and resuspended in lysis buffer with a
protease inhibitor cocktail (Roche Diagnostics). Proteins were
fractionated by 8% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in reducing conditions, then trans-
ferred to polyvinylidene difluoride filters (PVDF, Boehringer
Mannheim) and probed with rabbit polyclonal anti-pSTAT4 IgG
(Zymed), rabbit polyclonal anti-pSTAT2 IgG (Upstate Biotech-
nology) or rabbit polyclonal anti-pSTAT1 IgG (New England
Biolabs), followed by the secondary antibody (horseradish
peroxidase (HRP)-conjugated goat anti-mouse or anti-rabbit IgG
(Jackson Immunoresearch). PVDF blots were developed with
SuperSignal WestPico kits (Pierce). The membranes were then
washed and reprobed with anti-STAT4 (Santa Cruz Biotechnol-
ogy), anti-STAT2 or anti-STAT1 (rabbit polyclonal IgG, Upstate
Biotechnology).
IFN-c production
Purified B cells (1610
6 per well) were cultured in 48-well plates
in 500 ml of 10% FCS/RPMI 1640 medium. They were
pretreated with recombinant IFN-a2b (2000 U/ml) for 18 h then
activated with SAC (1:10 000 v/v) for 48 h. IFN-c was assayed in
the supernatants (human IFN-c ELISA, R&D).
Statistical Analysis
Wilcoxon paired t-test was used with Bonferroni correction.
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